QCLS.US Q/C Technologies, Inc.
- Market cap
- USD 2.74M
- P/E
- 0.1x
- P/B
- 0.16x
- ROE
- -72.8%
- Dividend yield
- 2.84%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QCLS.US undervalued?
Graham numberThe Graham number of Q/C Technologies, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Q/C Technologies, Inc. fundamental analysis
No fundamental analysis for Q/C Technologies, Inc. yet.
Q/C Technologies, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog …
Full company profileQ/C Technologies, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Q/C Technologies, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -29.5K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Operating Income | -9.49M | -28.8M | -15.3M | -17.1M | -10.2M | -9.85M | -14.9M |
| EBITDA | -8.27M | -29.3M | -15.2M | -16.4M | -8.66M | -11.6M | -7.72M |
| Net Income | -9.49M | -29.9M | -15.2M | -4.00M | -23.4M | -11.6M | -11.7M |
| EPS | -8,075 | -2,561 | -1,174 | -259 | -959 | -6.72 | -1.38 |
| Balance Sheet | |||||||
| Total Assets | 677K | 24.8M | 17.5M | 17.9M | 21.4M | 41.2M | 21.3M |
| Total Liabilities | 5.93M | 1.17M | 2.84M | 5.09M | 6.70M | 19.4M | 2.18M |
| Shareholders' Equity | -5.26M | 23.6M | 14.7M | 12.8M | 14.7M | 21.8M | 16.1M |
| Cash & Short-term Investments | 148K | 11.6M | 4.84M | 4.92M | 8.52M | 15.8M | 9.39M |
| Total Debt | 4.13M | 149K | 142K | 48.9K | 10.6K | - | 158K |
| Cash Flow | |||||||
| Operating Cash Flow | -11.9M | -19.5M | -12.3M | -13.0M | -8.98M | -9.07M | -8.85M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01M | 195K |
| Free Cash Flow | -11.9M | -19.5M | -12.3M | -13.0M | -8.98M | -11.1M | -9.05M |
| Ratios | |||||||
| ROE | - | -126.4% | -103.4% | -31.3% | -158.7% | -53.5% | -72.8% |
| ROA | -1,402.1% | -120.5% | -86.6% | -22.4% | -109.0% | -28.2% | -55.1% |
| Debt to Equity | - | 0.01x | 0.01x | 0.00x | 0.00x | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Q/C Technologies, Inc. dividends
- Dividend yield
- 2.84%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 77.6K | 0.04 | - |
| 2024 | USD 1.36M | 56 | - |
| 2023 | USD 1.45M | 94 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:100 on Sep 2, 2025.
Who owns Q/C Technologies, Inc.
- Insiders 7.53%
- Institutions 5.78%
- Public & others 86.69%
- Shares outstanding 8.19M
- Free float 7.90M
Top funds holding QCLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 50.0K | 0.61% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 13.0K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 11.4K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 5.67K | 0.07% | 0.00% | Aug 2026 |
| Dimensional US Small Cap ETF | 5.57K | 0.07% | 0.00% | Oct 2026 |
Top institutions holding QCLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 115K | 1.40% | +206.66% | Jun 2026 |
| Quinn Opportunity Partners LLC | 91.8K | 1.12% | -25.36% | Sep 2026 |
| Jane Street Group LLC | 87.2K | 1.07% | -30.86% | Jun 2026 |
| Geode Capital Management, LLC | 70.7K | 0.86% | +49.15% | Jun 2026 |
| UBS Group AG | 58.9K | 0.72% | -24.48% | Jun 2026 |
| Balyasny Asset Management LLC | 57.7K | 0.70% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 50.4K | 0.62% | +124.84% | Jun 2026 |
| ADAR1 Capital Management LLC | 50.0K | 0.61% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 43.1K | 0.53% | +176.78% | Jun 2026 |
| State Street Corp | 25.3K | 0.31% | +96.09% | Jun 2026 |
| Northern Trust Corp | 18.0K | 0.22% | 0.00% | Jun 2026 |
| Pin Oak Investment Advisors Inc | 3.50K | 0.04% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.04K | 0.01% | -34.53% | Jun 2026 |
| Barclays PLC | 950.00 | 0.01% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 100.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 19.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 9.00 | 0.00% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Bryn Mawr Trust Company | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 0.00 | 0.00% | -100.00% | Sep 2026 |
Q/C Technologies, Inc. company profile
- Company name
- Q/C Technologies, Inc.
- Ticker
- QCLS.US
- Exchange
- USA Stocks
- Listed since
- Jan 23, 2014
- Sector
- Technology
- Industry
- Pharmaceuticals
- Employees
- 3
- Fiscal year end
- December
- Address
- 1185 Avenue of the Americas, New York, NY, United States, 10036
- Phone
- 856 848 8698
- Website
- qctechnologies.com
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Q/C Technologies, Inc. management
5- Mr. Joshua N. SilvermanExecutive Chairman of the Board · born 1970
- Mr. Ian Thomas Rhodes CPAChief Financial Officer · born 1973
- Dr. Mitchell Glass M.D.Chief Medical Officer & Director · born 1952
- Mr. Yossef EhrlichmanChief Technology Officer · born 1977
- Robert SchatzInvestor Relations Officer